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Conclusion: This retrospective study shows that the 
SUVmax50 pre-therapeutic signal correlates with the post-
therapeutic recurrences in the majority of patients. Pre-
therapeutic PET/CT or planning PET/CT is a useful tool to 
guide the future dose escalation studies. 
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Purpose or Objective: 
Background: There is great potential to utilise a large range 
of retrospective clinical data as an evidence base in decision 
support systems (DSS) for cancer prognosis and subsequent 
personalised treatment decisions. Recently, there were 
several DSSs built for this purpose using machine learning 
tools, mainly regression models, Bayesian Networks (BN) and 
Support Vector Machines (SVM). These machine learning tools 
provide only a prediction of a class (decision), based on input 
attributes that were used to build the model, without 
providing additional information to clinicians about how and 
why this prediction was made. 
Objective: To investigate the performance of an alternative 
machine learning tool in building a lung cancer radiotherapy 
DSS that provides clinicians with an estimated prediction 
together with the influencing attributes and their values 
(evidence) in supporting the decision reached. This will 
provide contextual justification to clinicians regarding the 
decisions, which will further help them in deciding whether 
to adopt the machine prediction or not. 
 
Material and Methods: A Non-Small Cell Lung Cancer 2 year 
survival prediction model was built, using data at Liverpool 
Cancer Therapy Centre in NSW, Australia. The attributes used 
to predict the survival were age, gender, ECOG, GTV and 
FEV1. The machine learning tool used is a Decision Tree 
which automatically extracts rules from the training data and 
formulates these as if-then-else patterns. A report of the 
used rules during the prediction process indicates the 
effective attributes used to reach the decision. SVM, 
Regression models and BN were built and tested using the 
same data set; however, BN possess less, and SVM/Regression 
models possess none, of this reporting capability as they are 
learned by analysing probabilities and numerical distances 
among data points associated with prediction class. 
 
Results: The DSS was learnt within the Liverpool Clinic with 
an unfiltered cohort of 4650 4686 patients. After filtering out 
patient records with missing values for the used attributes 
the cohort was reduced to 97 patients treated radically. The 
area under curve of the Decision Tree, SVM, Regression Model 
and BN when tested using a rigorous 10 fold cross-validation 
method respectively was 0.62, 0.62, 0.63 and 0.6. There is no 
significant difference in the performance between the four 
tools examined, however, the decision tree also generates an 
understandable context with every prediction made as a list 
of supporting attributes like the example in Figure 1. 
 
 
 
Conclusion: It is possible to build a DSS for NSCLC data that 
provides a prediction with additional information justifying 
the decision with similar performance as the commonly 
utilised SVM, BN and regression tools. To improve the 
performance and avoid over fitting, more diverse and 
complete training data is needed by incorporating data from 
other centres to the learning process using distributed 
learning. 
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Purpose or Objective: Stereotactic body radiotherapy (SBRT) 
is an attractive modality for the definitive treatment of 
oligometastatic or unresectable primary lung malignancies. 
Proximity of the tumor to adjacent organs-at-risk (OAR) may 
limit delivery of a sufficiently ablative dose. The ability to 
adapt to tumor response during treatment may improve OAR 
sparing and/or allow dose escalation. This study aimed to 
evaluate the degree of daily interfractional variation in gross 
tumor volume (GTV) during SBRT for patients with 
oligometastatic or unresectable primary malignancy of the 
central thorax using a magnetic resonance image guided 
radiotherapy (MR-IGRT) treatment system. 
 
Material and Methods: Eleven patients with unresectable 
primary or oligometastatic malignancy of the central thorax 
were treated at our institution with extended fractionation 
SBRT on a clinical MR-IGRT system. Treatment regimens 
consisted of 60 Gy in 12 fractions (n=8) or 62.5 Gy in 10 
fractions (n=3). For each treatment fraction, low-field (0.35 
Tesla) MR setup imaging was acquired as part of routine 
clinical practice. Daily GTV was retrospectively defined on 
MR image sets for all patients at each of 10 or 12 fractions, 
using initial GTVs from CT simulation as a template. Daily 
tumor volumes were then recorded and compared for each 
patient to evaluate for interfractional change in tumor 
volume. 
